axelopran
PreclinicalSmall molecule
axelopran is one of 9 small molecule programs targeting Head and Neck Squamous Cell Carcinoma (HNSCC). It is currently in Preclinical.
2
Indications
3
Total Trials
3
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Head and Neck Squamous Cell Carcinoma (HNSCC)
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Libtayo
RegeneronPhase 2
Opdualag
Bristol-Myers SquibbPhase 2
Erbitux
IImclone
Phase 1
FDC Fianlimab+cemiplimab
RegeneronPhase 2
Ezabenlimab
Boehringer IngelheimPhase 1
Pembolizumab
SShanghai JMT-Bio Inc.
Preclinical
axelopran
HHealthPartners Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for axelopran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHealthPartners Institute